###begin article-title 0
###xml 110 115 <span type="species:ncbi:9606">women</span>
A49T, V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and breast cancer risk in Japanese women
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 445 451 441 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
Breast cancer is hormone related, as are cancers of the endometrium, ovary, and prostate. Several studies have suggested that higher extracellular levels of androgens are associated with breast cancer risk, while biological evidence indicates that androgens are protective. The codon 49 alanine to threonine substitution (A49T), codon 89 valine to leucine substitution (V89L) and TA repeat polymorphisms of the steroid 5alpha-reductase type II (SRD5A2) gene are considered functional with respect to enzyme activity converting testosterone into dihydrotestosterone. To test the hypothesis that these three polymorphisms are associated with risk of breast cancer, a case-control study was conducted with patients of Aichi Cancer Center Hospital.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 19 27 <span type="species:ncbi:9606">patients</span>
The cases were 237 patients histologically diagnosed with breast cancer, and the controls were 185 noncancer outpatients. DNA from peripheral blood was genotyped by PCR methods.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 104 107 104 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 262 265 262 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 332 335 332 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 362 365 362 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 401 404 401 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 462 465 462 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 495 498 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 506 509 506 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 575 576 575 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 344 349 <span type="species:ncbi:9606">women</span>
The threonine allele of A49T was not found in our subjects. Compared with the V/V genotype of V89L, the L/L genotype was associated with a decreased risk (crude odds ratio [OR] = 0.61, 95% confidence interval [CI] = 0.36-1.05). This was also the case for the TA(9/9) genotype, with an OR of 0.58 (95% CI = 0.13-2.63) relative to TA(0/0). Among women with the TA(0/0) genotype, however, the OR for the L/L genotype was 0.46 (95% CI = 0.24-0.88) compared with the V/V genotype, and those with the V/V and TA(0/0) genotypes had the highest risk. The haplotype with the L and TA(9) repeat alleles was not found.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 62 67 <span type="species:ncbi:9606">women</span>
This study is the first to our knowledge focusing on Japanese women, suggesting that SRD5A2 polymorphisms might have an association with breast cancer risk. Further large-sample studies will be required to confirm the association and to assess any interactions with environmental factors.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 669 677 669 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 678 679 678 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 756 757 756 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 821 822 821 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 583 588 <span type="species:ncbi:9606">human</span>
###xml 716 721 <span type="species:ncbi:9606">human</span>
###xml 745 754 <span type="species:ncbi:10090">nude mice</span>
Breast cancer is a hormone-related cancer, as are cancers of the endometrium, ovary, and prostate [1]. Although the molecular mechanisms involved in initiation and progression are poorly understood, there is evidence that extracellular levels of androgens are associated with the development of breast cancer [2,3]. Nested case-control studies have shown that increased circulating levels of testosterone elevate the risk of breast cancer [4-6]. Experimental studies suggest, however, that androgens exert a potent antiproliferative effect on the growth of several hormone-sensitive human breast cancer cells under both basal and estrogen-induced incubation conditions in vitro[7], as well as in vivo, using ZR-75-1 human breast cancer cells in nude mice [8]. Androgens have been used for the treatment of breast cancer [9,10].
###end p 10
###begin p 11
###xml 170 176 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A1</italic>
###xml 239 245 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 393 395 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 266 271 <span type="species:ncbi:9606">human</span>
Steroid 5alpha-reductase converts testosterone to the metabolically more active dihydrotestosterone, which has two isoforms; type I expressed in liver, skin and scalp by SRD5A1 located on chromosome 5; and type II expressed in prostate by SRD5A2 on chromosome 2. In human breast invasive ductal carcinomas, both type I (58% of 60 cases) and type II (15% of 60 cases) are reportedly expressed [11].
###end p 11
###begin p 12
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The SRD5A2 gene consists of five exons and four introns, and encodes a 254 amino acid protein [12]. Several single nucleotide polymorphisms have been reported in the five exons [13]. However, only two of these polymorphisms (A49T and V89L), along with the variable number of dinucleotide TA repeat polymorphisms in the 3' untranslated region, have been examined concerning risk and prognosis of cancers.
###end p 12
###begin p 13
###xml 193 195 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 318 321 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 332 334 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 214 217 <span type="species:ncbi:9606">men</span>
The V89L polymorphism that substitutes leucine for valine at codon 89 is reported to reduce almost 30% of androstanediol glucuronide, a serum marker of 5alpha-reductase activity, among Asians [14]. Among Caucasian men, a 10% insignificantly lower androstanediol glucuronide level was observed for individuals with the L/L genotype [15].
###end p 13
###begin p 14
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 447 450 447 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 459 462 459 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
The TA repeat polymorphism reportedly has 10 alleles with 0, 8, 9, 10, 17, 18, 19, 20, 21, and 22 repeats, among which the 0-repeat allele (designated TA(0)) and the 9-repeat allele (designated TA(9)) are common. The alleles with more than 10 repeats were found exclusively in African-Americans, the highest risk ethnic group of prostate cancer [16]. No significant difference in serum androstanediol glucuronide level was reported between the TA(0/0) and TA(0/9) genotypes among the Chinese [17].
###end p 14
###begin p 15
###xml 81 82 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
In the A49T polymorphism that substitutes threonine for alanine at codon 49, the T allele was reported to be the allele with the higher enzyme activity [18].
###end p 15
###begin p 16
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 671 673 671 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
A49T, V89L and TA repeat polymorphisms could be associated with risk of breast cancer. To our knowledge, however, there have been no studies on the potential association between SRD5A2 gene polymorphisms and breast cancer risk except for one study of the TA repeat polymorphism, which demonstrated no significant difference in the genotype distribution between 141 cases and 70 controls [19]. However, several studies for prostate cancer risk have been reported [17,18,20-26]. Two reports have been published by the same research group in Italy concerning roles in breast cancer prognosis, one regarding the TA repeats [19] and the other regarding the V89L polymorphism [27].
###end p 16
###begin p 17
###xml 82 88 82 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 125 130 <span type="species:ncbi:9606">women</span>
The present study aims to examine the associations between three polymorphisms of SRD5A2 and breast cancer risk for Japanese women using a prevalent case-control study conducted at Aichi Cancer Center.
###end p 17
###begin title 18
Materials and methods
###end title 18
###begin title 19
Study population
###end title 19
###begin p 20
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
The cases were female breast cancer patients visited at Aichi Cancer Center Hospital [28]. Between March 1999 and April 2000, 247 breast cancer cases were interviewed, and 243 were enrolled. Two patients refused to provide a blood sample after enrollment, and two blood samples were not stored. Among the 239 blood samples, two samples of extracted DNA had concentrations too low to be genotyped. The remaining 237 samples were used in the present study. The pathology of breast tumors was examined for 204 cases at Aichi Cancer Center Hospital, and for 33 cases at other hospitals.
###end p 20
###begin p 21
The controls were 187 female cancer-free outpatients, mainly presenting at the clinics for gastroenterology, breast surgery, and gynecology of Aichi Cancer Center Hospital. They were also invited during March 1999 and April 2000. One serum sample was not stored, and one had too low a DNA concentration to be genotyped. Only 185 controls were therefore available.
###end p 21
###begin p 22
###xml 4 16 <span type="species:ncbi:9606">participants</span>
All participants were given a self-administrated questionnaire. Information was requested on demography, family history of breast cancer (mother and/or sisters), and food intake before the appearance of symptoms. Interviewers checked all written responses to ensure that there were no unanswered questions at the time of questionnaire collection.
###end p 22
###begin title 23
Genetic analyses
###end title 23
###begin p 24
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 476 477 474 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 846 847 814 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 895 896 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
PCR amplification of the A49T polymorphism was conducted by a PCR with confronting two-pair primers method [29], using the following primers: 5'-GCG GAC ACG GGT GGC GTC-3', 5'-GAA CCA GGC GGC GCG GGT-3', 5'-GCG GCT ACC CGC CTG CCA G-3', and 5'-CGC CGG GAG CAG GGC AGT-3'. Aliquots of 30-100 ng genomic DNA were mixed with 25 mul reaction liquid containing 0.18 mmol/l dNTPs, 12.5 pmol each primer, 0.5 units AmpliTaq Gold, and 2.5 mul GeneAmp 10xPCR buffer with 15 mmol/l MgCl2 (Perkin-Elmer Corporation, Foster City, CA, USA). Amplification conditions were set as follows: a 10-min initial denaturation at 95degreesC, followed by 30 cycles at 95degreesC for 1 min denaturation, 64degreesC for 1 min annealing and 72degreesC for 1 min extension, and the final extension was at 72degreesC for 5 min. Genotyping was 403 and 209 bp for the alanine (A) allele, and 430 and 257 bp for the threonine (T) allele.
###end p 24
###begin p 25
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
V89L polymorphisms were genotyped by a PCR-restriction fragment length polymorphism method described by Yamada et al. [24].
###end p 25
###begin p 26
###xml 279 280 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0</italic>
###xml 311 312 305 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 369 372 363 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 381 384 375 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
Genotypes of the TA repeat polymorphism were determined using the primers 5'-GCT GAT GAA AAC TGT CAA GCT-3' and 5'-ACT CTA AGC AGA CAC CAC TCA G-3', with PCR conditions the same as for the A49T polymorphism except for annealing at 54degreesC. Amplified DNA was 129 bp for the TA(0) allele and 147 bp for the TA(9) allele. Genotyping was confirmed for two samples of TA(0/0) and TA(9/9) by DNA sequencing.
###end p 26
###begin title 27
Statistical methods
###end title 27
###begin p 28
The Stata 7.0 software package (STATA Corp., College Station, TX, USA) was used to analyze the results, with the Pearson chi-square test employed to compare the distribution of characteristics between cases and controls. ORs and 95% CIs were estimated by unconditional logistic regression analysis.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
Characteristics of the study subjects
###end title 30
###begin p 31
###xml 267 268 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 380 385 <span type="species:ncbi:9606">women</span>
Our research included 237 female breast cancer cases and 185 female controls. The means and the standard deviations of age were 50.5 +/- 8.5 years for cases and 52.9 +/- 10.2 years for controls. The other characteristics of cases and controls are summarized in Table 1. No differences in the distributions were observed between cases and controls, except for the menopause state (women without menstruation caused by medication or surgery were included in the premenopause group if aged <50 years) and family history of breast cancer (mother and/or sisters).
###end p 31
###begin title 32
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
Distributions of SRD5A2 polymorphisms and crude ORs
###end title 32
###begin p 33
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A/A</italic>
Table 2 presents the distributions of SRD5A2 polymorphisms. All subjects were found to have the A/A genotype for A49T polymorphism.
###end p 33
###begin p 34
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 101 104 101 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/L</italic>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 233 236 233 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 416 421 <span type="species:ncbi:9606">women</span>
###xml 588 593 <span type="species:ncbi:9606">women</span>
###xml 613 618 <span type="species:ncbi:9606">women</span>
Two cases and two controls could not be genotyped for the V89L polymorphism. Frequencies of the L/L, V/L and V/V genotypes were 21.7, 52.3, and 26.0% for cases, and 32.8, 43.2, and 24.0% for controls, respectively. Compared with the V/V genotype, the L/L genotype demonstrated a marginally significant OR of 0.61 (95% CI = 0.36-1.05). Table 3 presents the results of the subgroup analysis. Although not significant, women with the L/L genotype had a reduced risk in any subgroup except those with a family history of breast cancer. There was no difference in the OR between premenopausal women and postmenopausal women. The significance of OR was marginal among the body mass index (BMI) <22 group.
###end p 34
###begin p 35
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0</italic>
###xml 74 75 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 104 107 104 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 113 116 113 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 316 319 316 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 469 472 469 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 479 482 479 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 293 298 <span type="species:ncbi:9606">women</span>
###xml 425 430 <span type="species:ncbi:9606">women</span>
###xml 524 529 <span type="species:ncbi:9606">women</span>
The present study found only two types of TA repeat alleles: TA(0) and TA(9). The frequencies of the TA(0/0), TA(0/9) and TA(9/9) genotypes were 75.9, 22.8, and 1.3% for cases, and 75.1, 22.7, and 2.2% for controls, respectively. No reduction in the OR was found for the TA(0/9) genotype, and women with genotype TA(9/9) were too few to be evaluated (Table 2). The difference in the OR was not observed between premenopausal women (OR = 0.85, 95% CI = 0.43-1.66 for TA(0/9) + TA(9/9) relative to TA(0/0)) and postmenopausal women (OR = 1.09, 95% CI = 0.59-2.01). Accordingly, no subgroup analysis was conducted.
###end p 35
###begin title 36
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
SRD5A2 polymorphisms and risk factors
###end title 36
###begin p 37
###xml 289 292 289 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 334 337 334 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/L</italic>
###xml 379 382 379 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 427 430 427 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 476 479 476 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 529 532 529 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 670 673 670 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 715 718 715 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/L</italic>
###xml 760 763 760 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 808 811 808 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 857 860 857 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 926 929 926 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 558 563 <span type="species:ncbi:9606">women</span>
The associations of the polymorphism genotypes with age at menarche, age at menopause, and BMI were examined among the present controls. No associations were observed with mean ages at menarche and at menopause. Mean age at menarche (standard deviation) was 13.6 years (1.5 years) for the V/V genotype, 13.7 years (1.8 years) for the V/L genotype, 13.7 years (1.8 years) for the L/L genotype, 13.7 years (1.8 years) for the TA(0/0) genotype, 13.7 years (1.6 years) for the TA(0/9) genotype, and 13.5 years (2.4 years) for the TA(9/9) genotype. Among control women with natural menopause, the mean age at menopause (standard deviation) was 50.5 years (2.7 years) for the V/V genotype, 50.1 years (3.8 years) for the V/L genotype, 50.1 years (3.6 years) for the L/L genotype, 50.8 years (3.7 years) for the TA(0/0) genotype, 49.6 years (2.6 years) for the TA(0/9) genotype, and there were no postmenopausal controls with the TA(9/9) genotype.
###end p 37
###begin p 38
###xml 127 130 127 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 109 114 <span type="species:ncbi:9606">women</span>
The mean BMI (standard deviation) was also similar among the subgroups according to genotype except for four women with the TA(9/9) genotype: 22.5 (3.1), 22.2 (3.0), and 21.9 (2.9) for the V89L polymorphism, and 22.3 (3.0), 22.1 (3.1), and 19.7 (0.4) for the TA repeat polymorphism, respectively.
###end p 38
###begin title 39
Relationship between V89L and TA repeat genotypes
###end title 39
###begin p 40
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 106 109 106 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 164 167 164 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 204 207 204 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The combined genotype frequency between TA repeat and V89L polymorphisms was also examined (Table 4). The V/V genotype among controls was 15.2% (21/138) for the TA(0/0) genotype, 46.3% (19/41) for the TA(0/9) genotype, and 100% (4/4) for the TA(9/9) genotype, while that among cases was 21.9% (39/178), 35.2% (19/54), and 100% (3/3), respectively. Fisher's exact test for 3 x 3 tables showed a significant association between the two genotype distributions both among cases and controls (P < 0.001).
###end p 40
###begin title 41
ORs for the combination of V89L and TA repeat polymorphisms
###end title 41
###begin p 42
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 187 190 187 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 198 201 198 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 303 306 303 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 314 317 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 83 88 <span type="species:ncbi:9606">women</span>
Table 5 presents the ORs for each combination of the two polymorphisms relative to women with the V/V and TA(0/0) genotypes, who had the highest risk of breast cancer. The combination of L/L and TA(0/0) had a significantly decreased risk, with an OR of 0.46 (95% CI = 0.24-0.88), and the combination of V/V and TA(9/9) showed the lowest, but insignificant, OR. The other three combinations indicated an intermediately reduced risk.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 437 443 437 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
Although one study reported that the effect of testosterone was cancelled by the adjustment of the estradiol level [30], several studies have provided epidemiological evidence that the serum level of testosterone is associated with the risk of breast cancer [2,4-6]. On the contrary, experimental data propose evidence that androgens are protective against breast cancer [7-10]. The present polymorphism study added the finding that the SRD5A2 genotypes with a lower enzyme activity may reduce the breast cancer risk.
###end p 44
###begin p 45
###xml 314 317 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 663 666 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 762 763 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 770 773 770 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 837 838 837 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 875 876 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 915 916 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 366 369 <span type="species:ncbi:9606">men</span>
###xml 510 513 <span type="species:ncbi:9606">men</span>
###xml 736 741 <span type="species:ncbi:9606">women</span>
###xml 825 828 <span type="species:ncbi:9606">men</span>
###xml 864 867 <span type="species:ncbi:9606">men</span>
###xml 904 907 <span type="species:ncbi:9606">men</span>
###xml 1001 1006 <span type="species:ncbi:9606">women</span>
Since the difference in enzyme activity by the genotypes was explained in the Introduction, the potential impact on hormone concentrations should be discussed. Although hormone levels are determined by activities of several enzymes and the influence of the genotypes may differ between females and males, the V89L L/L genotype with low activity was found in Chinese men to be associated with a significantly higher concentration of testosterone, but not with dihydrotestosterone concentration [17]. In British men, the genotype had a significant association with a lower serum level of testosterone and free testosterone [15]. The present study suggests that the L/L genotype might decrease the risk for breast cancer, especially among women with BMI <22 (Table 3). The L/L genotype was reported to be more frequent in Asian men (21.6%, n = 102) than in Caucasian men (4.1%, n = 49) and African-American men (3.2%, n = 95) [14], which may partly explain the low incidence in breast cancer among Asian women.
###end p 45
###begin p 46
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0</italic>
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 178 181 178 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 195 198 195 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 215 218 215 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 249 250 249 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 269 272 269 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 286 289 286 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 306 309 306 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 352 355 352 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 369 372 369 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 122 127 <span type="species:ncbi:9606">women</span>
Of the TA repeat alleles, only TA(0) and TA(9) were observed in our subjects. The present genotype frequency for Japanese women was similar to those in Italy (n = 70; 79% for TA(0/0), 17% for TA(0/9), and 4% for TA(9/9)) [19], in the United States (n = 802; 75% for TA(0/0), 22% for TA(0/9), and 2% for TA(9/9)) [20], and in China (n = 304; 82% for TA(0/0), 17% for TA(0/9), and 1% for TA(9/9)) [17].
###end p 46
###begin p 47
###xml 73 76 73 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 108 111 108 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 314 317 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/9</italic>
###xml 329 332 329 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 393 394 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 508 511 508 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 481 486 <span type="species:ncbi:9606">women</span>
The present study demonstrated a tendency for risk reduction with the TA(9/9) genotype compared with the TA(0/0) genotype (Table 2). In a small-sized study with 141 cases and 70 controls in Italy, there was no significant association between the TA repeat polymorphism and risk of breast cancer [19], while the TA(0/9) or the TA(9/9) genotype demonstrates a reduction in the risk for relapse (P = 0.043). The combination analysis of TA repeat and V89L polymorphisms suggested that women with the TA(0/0) and V/V genotypes had the highest risk for breast cancer (Table 5). This is a plausible finding biologically, because the genotype is regarded to have the highest enzyme activity. There are no studies that examine the joint effect on prostate cancer.
###end p 47
###begin p 48
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 181 182 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 386 387 386 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 490 491 490 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T</italic>
###xml 302 305 <span type="species:ncbi:9606">men</span>
###xml 343 346 <span type="species:ncbi:9606">men</span>
The lack of alanine to threonine substitution in SRD5A2 codon 49 in our subjects is in accordance with a previous study in Japan [24] and another in China [17], suggesting that the T allele may not exist among Asians. The reported frequency of the T allele was 1.0% of 522 alleles for African-American men and 2.3% of 400 alleles for Hispanic men [18]. In Finland, individuals with the T allele were 5.8% (n = 588) for donated blood and cancer-free autopsy samples [26]. The absence of the T allele among Asians may indicate that the polymorphism occurred relatively recently in comparison with V89L and TA repeat polymorphisms. For examining the effects of V89L and TA repeat polymorphisms, our subjects had an advantage in that there was no need to consider the potential effect of A49T as a confounder or a modifier.
###end p 48
###begin p 49
###xml 43 44 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 77 78 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 93 94 93 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9/9</italic>
###xml 124 127 124 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
The present study demonstrates that the TA(9) allele only coexisted with the V allele (Table 4). The absence of the TA(9/9)-L/L genotype indicated a strong linkage disequilibrium. Another study in Italy unearthed the same result [27].
###end p 49
###begin title 50
Conclusions
###end title 50
###begin p 51
###xml 108 118 108 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2 V/V</italic>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0/0</italic>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L</italic>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">9</italic>
###xml 66 71 <span type="species:ncbi:9606">women</span>
The present study suggests an reduced risk of breast cancer among women without the genotype combination of SRD5A2 V/V and TA(0/0). An absence of the genotypes necessitating the L-TA(9) haplotype indicated linkage disequilibrium between V89L and TA repeat polymorphisms. There appears to be no substitution of alanine to threonine in codon 49 among the Japanese. Since the metabolic pathway of steroid hormones is complicatedly regulated, activity of a single metabolic enzyme cannot solely describe the risk of breast cancer. In addition, to confirm the association observed in the present study, a systematic approach taking account of potentially relating polymorphisms is desirable in the near future.
###end p 51
###begin title 52
Abbreviations
###end title 52
###begin p 53
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L/L</italic>
###xml 190 196 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A2</italic>
###xml 281 284 277 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/L</italic>
###xml 303 306 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V/V</italic>
A49T = codon 49 alanine to threonine substitution; BMI = body mass index; bp = base pairs; CI = confidence interval; L/L = leucine/leucine; OR = odds ratio; PCR = polymerase chain reaction; SRD5A2 = steroid 5alpha-reductase type II; V89L = codon 89 valine to leucine substitution; V/L = valine/leucine; V/V = valine/valine.
###end p 53
###begin title 54
Acknowledgements
###end title 54
###begin p 55
This work was supported in part by a Grant-in-Aid for Scientific Research (grant number 12670383) from the Ministry of Education, Science, Sports, Culture and Technology of Japan. CY was supported by the Japan-China Sasakawa Medical Fellowship.
###end p 55
###begin article-title 56
Hormonal carcinogenesis.
###end article-title 56
###begin article-title 57
New hormone-related markers of high risk to breast cancer.
###end article-title 57
###begin article-title 58
Characteristics of cystic breast disease with special regard to breast cancer development.
###end article-title 58
###begin article-title 59
Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk.
###end article-title 59
###begin article-title 60
Serum sex hormone levels after menopause and subsequent breast cancer.
###end article-title 60
###begin article-title 61
Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer.
###end article-title 61
###begin article-title 62
Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation.
###end article-title 62
###begin article-title 63
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice.
###end article-title 63
###begin article-title 64
Androgens and breast cancer.
###end article-title 64
###begin article-title 65
###xml 106 111 <span type="species:ncbi:9606">women</span>
Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis.
###end article-title 65
###begin article-title 66
###xml 21 26 <span type="species:ncbi:9606">human</span>
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
###end article-title 66
###begin article-title 67
###xml 13 18 <span type="species:ncbi:9606">human</span>
Structure of human type II 5 alpha-reductase gene.
###end article-title 67
###begin article-title 68
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Identification of missense mutations in the SRD5A2 gene from patients with steroid 5alpha-reductase 2 deficiency.
###end article-title 68
###begin article-title 69
A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
###end article-title 69
###begin article-title 70
###xml 124 127 <span type="species:ncbi:9606">men</span>
The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
###end article-title 70
###begin article-title 71
###xml 27 32 <span type="species:ncbi:9606">human</span>
Genetic variability of the human SRD5A2 gene: implication for prostate cancer risk.
###end article-title 71
###begin article-title 72
Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
###end article-title 72
###begin article-title 73
###xml 107 110 <span type="species:ncbi:9606">men</span>
Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
###end article-title 73
###begin article-title 74
TA repeat polymorphism of the 5alpha-reductase gene and breast cancer.
###end article-title 74
###begin article-title 75
A polymorphism of the 5 alpha reductase gene and its association with prostate cancer: a case-control analysis.
###end article-title 75
###begin article-title 76
The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer.
###end article-title 76
###begin article-title 77
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.
###end article-title 77
###begin article-title 78
Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
###end article-title 78
###begin article-title 79
Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
###end article-title 79
###begin article-title 80
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.
###end article-title 80
###begin article-title 81
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRD5A21</italic>
A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A21) is not associated with prostate cancer in Finland.
###end article-title 81
###begin article-title 82
###xml 30 35 <span type="species:ncbi:9606">human</span>
Codon 89 polymorphisms in the human 5alpha-reductase gene in primary breast cancer.
###end article-title 82
###begin article-title 83
Possible association of beta2- and beta3-adrenergic receptor gene polymorphisms with susceptibility to breast cancer.
###end article-title 83
###begin article-title 84
Polymerase chain reaction with confronting two-pair primers for polymorphism genotyping.
###end article-title 84
###begin article-title 85
###xml 119 124 <span type="species:ncbi:9606">women</span>
Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women.
###end article-title 85
###begin title 86
Figures and Tables
###end title 86
###begin p 87
Characteristics of the study subjects
###end p 87
###begin p 88
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
* Age at diagnosis for cases and at study enrollment for controls.
###end p 88
###begin p 89
Genotype distributions of A49T, V89L and TA repeat polymorphisms
###end p 89
###begin p 90
Percentages are shown in parentheses.
###end p 90
###begin p 91
Crude odds ratios and 95% confidence intervals for V89L polymorphism by subgroup
###end p 91
###begin p 92
Genotype distributions of V89L and TA repeat polymorphisms
###end p 92
###begin p 93
Percentages are shown in parentheses.
###end p 93
###begin p 94
Odds ratios and 95% confidence intervals for combinations of V89L and TA repeat polymorphisms
###end p 94
###begin p 95
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">*</sup>
Data presented as odds ratio (95% confidence interval). * Adjusting for family history of breast cancer and menopause state.
###end p 95

